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Abstract
TCF7L2 is the susceptibility gene for Type 2 diabetes (T2D) with the largest effect on disease risk that has been discovered to
date. However, the mechanisms by which TCF7L2 contributes to the disease remain largely elusive. In addition, epigenetic
mechanisms, such as changes in DNA methylation patterns, might have a role in the pathophysiology of T2D. This study
aimed to investigate the differences in terms of DNA methylation profile of TCF7L2 promoter gene between type 2 diabetic
patients and age- and Body Mass Index (BMI)- matched controls. We included 93 type 2 diabetic patients that were recently
diagnosed for T2D and exclusively on diet (without any pharmacological treatment). DNA was extracted from whole blood
and DNA methylation was assessed using the Sequenom EpiTYPER system. Type 2 diabetic patients were more insulin
resistant than their matched controls (mean HOMA IR 2.6 vs 1.8 in controls, P,0.001) and had a poorer beta-cell function
(mean HOMA B 75.7 vs. 113.6 in controls, P,0.001). Results showed that 59% of the CpGs analyzed in TCF7L2 promoter had
significant differences between type 2 diabetic patients and matched controls. In addition, fasting glucose, HOMA-B, HOMA-
IR, total cholesterol and LDL-cholesterol correlated with methylation in specific CpG sites of TCF7L2 promoter. After
adjustment by age, BMI, gender, physical inactivity, waist circumference, smoking status and diabetes status uniquely
fasting glucose, total cholesterol and LDL-cholesterol remained significant. Taken together, newly diagnosed, drug-naı¨ve
type 2 diabetic patients display specific epigenetic changes at the TCF7L2 promoter as compared to age- and BMI-matched
controls. Methylation in TCF7L2 promoter is further correlated with fasting glucose in peripheral blood DNA, which sheds
new light on the role of epigenetic regulation of TCF7L2 in T2D.
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Introduction
Type 2 diabetes (T2D) results from an interaction of genetic risk
and environmental factors[1]. The heritability estimates for T2D
range from 20% to 80%. The evidence for heritability has been
proven with different studies, such as population, family and twin-
based studies[2,3]. Through genome-wide association studies, over
60 loci have been associated with T2D risk[1]. However, the
genetic loci discovered to date explain only a small part of the T2D
heritability[1]. Reasons for the observed ‘‘missing heritability’’ in
T2D include gene-environment interactions, the role of gene
variants and epigenetics[1]. Epigenetics refer to heritable changes
in gene function that occur without a change in nucleotide
sequence. Epigenetic mechanisms could provide a molecular
explanation for some unresolved issues in T2D[4], such as
discordance within monozygotic twins[5], interindividual variation
in age of onset, disease severity and effect of lifestyle factors on
T2D risk. Indeed, recent studies propose that specific changes in
the epigenome are associated with the onset and progression of
diabetes[6,7,8,9]. DNA methylation is the best studied epigenetic
modification and influences transcriptional regulation[10]. DNA
methylation is a reversible process that can be modulated by both
stochastic and environmental stimuli[11]. On the other hand,
TCF7L2 remains the most significant and consistently replicated
gene linked to T2D[1,12]. TCF7L2 has the strongest effect for
T2D (average OR 1.37)[13]) and encodes a transcription factor
implicated in wnt signaling and proglucacon transcription [14]. It
has been shown that TCF7L2 expression in human islets was
increased 5-fold in T2D and overexpression of TCF7L2 in human
islets reduced glucose-stimulated insulin secretion[15]. However,
the precise role of TCF7L2 with regard to T2D risk is still under
investigation. As DNA methylation influences gene expression, we
speculated that TCF7L2 gene could be affected by alterations in
DNA methylation in type 2 diabetic patients. Considering that
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DNA methylation occurs principally in the upstream regulatory
regions of the genes[16], we concentrated on the promoter of
TCF7L2 gene. Previous studies have shown that disease-related
methylation may be reflected in accessible tissues such as
peripheral blood[17].
The aim of this study was to compare the epigenetic profile
(defined here as the pattern of DNA methylation on TCF7L2
promoter in DNA from peripheral blood) between type 2 diabetic
patients and age- and BMI-matched controls.
Materials and Methods
Ethics Statement
This study was approved by the Clinical research ethical
committee of the Hospital Clı´nic, Barcelona, Spain (25th
November 2010, register number 2010/6162) and complies with
all laws and international ethics guidelines outlined in the
Declaration of Helsinki. All human subjects provided written,
informed consent. All samples and clinical data collected were
anonymised at source.
Study design and subjects included
We conducted a case-control study where cases were defined as
patients suffering from T2D that were treated only by diet. Cases
and controls were recruited from the same primary health center.
Eligibility criteria for inclusion of cases and controls were applied
as previously cited[18]. Briefly, eligibility criteria for cases were the
following: clinical diagnosis of T2D, adequate glycemic control
after a period of minimum six months of low-carbohydrate diet
and lifestyle interventions, no pharmacological therapy for T2D
needed to achieve the glycemic control. In case oral medication
was needed for optimal glycemic control, those patients were
excluded from the study. Diagnosis of T2D was done following
ADA recommendations[19]. Eligibility criteria for controls were as
follows: a negative oral glucose tolerance test (OGTT) at
recruitment, no previous diagnosis of T2D or prediabetes, no
chronic treatment with oral steroids. All controls had an OGTT
conducted to confirm they did not have any glucose intolerance.
Controls were frequency matched (i.e. match on cell instead of
individual[20]) on age and BMI to cases. Physical inactivity was
assessed by asking the subjects if they practised at least 30 min of
exercise by day. The subjects who answered ‘‘no’’ were classified
as ‘‘physically inactive’’. Subjects addicted to alcoholism or with a
history of alcoholism were excluded from the study. Metabolic
profile and DNA methylation of TCF7L2 promoter in peripheral
blood DNA profile was studied for all subjects (93 cases and 93
controls).
Metabolic assessments
All subjects were examined by anthropometric measurements
and had fasting metabolic assessments at recruitment. These
assessments included fasting serum glucose, fasting serum insulin,
glycohemoglobin A1 (HbA1), total cholesterol, triglycerides, high
density level (HDL) cholesterol, low density level (LDL) cholester-
ol, hepatic profile, homeostatic model assessment to quantifiy
insulin resistance (HOMA-IR) and homeostatic model assessment
to quantifiy beta-cell function (HOMA-B). HOMA-IR was
calculated as follows: HOMA-IR = (FSI 6 FSG)/22.5 [21];
HOMA-B = (206FSI)/(FSG 23.5), where FSI is the fasting
serum insulin concentration (mU/l) and FSG is fasting serum
glucose (mmol/l)[22]. All laboratory analyses were performed at
the central biochemical laboratory of the Hospital Clinic,
Barcelona, Spain.
DNA methylation analysis
Whole blood samples were stored in the Biobank Hospital
Clı´nic-IDIBAPS; Barcelona, Spain[23]. Genomic DNA was
extracted from whole blood for all the subjects studied using
standards procedures from the Biobank[23]. Sequenom’s Mas-
sARRAY platform was used to perform quantitative methylation
analysis[24]. This system utilizes MALDI-TOF mass spectrometry
in combination with RNA base-specific cleavage (MassCLEAVE).
A detectable pattern is then analyzed for methylation status. PCR
primers for the amplification of the promoter of TCF7L2 gene
were designed using Epidesigner (See Appendix S1). Sequenom’s
EpiTYPER procedure and protocols include an intern quality
control of the methylation data[25]. Bisulfite conversion was done
for all samples (all cases and controls) together, with the same
reactive preparation, and the same operator. The methylation
analysis was done during the same day for all the samples (cases
and controls). Methylation data was generated in duplicate for
each CpG. There was one run for all cases and another one for all
controls, and all were done by the same operator during the same
day in the same machine. A fully methylated positive control was
included for each run.
Statistical analysis
Methylation data are generated as b values between 0 and 1,
indicating percentage methylation of the original template[26].
Due to the high variability of methylation data over the genomic
region analyzed, we decided to do the analysis using each CpG site
individually. Descriptive data are presented as the mean and
standard deviation (SD) for continuous outcomes, or number and
percentage (%) for categorical outcomes. HOMA-IR, HOMA-B,
and insulin were compared using non-parametric Mann-Whitney
U test because normality and equality of variance could not be
assumed. Student’s t test was used for the comparison of the rest of
continuous outcomes and Chi-square test for categorical out-
comes. Methylation differences between cases and controls were
studied by comparing the methylation means in each CpG site
using a non-parametric test (Mann-Whitney U test). Logistic
regression models adjusting for age, BMI, gender, waist circum-
ference, smoking status and physical inactivity were built to
confirm the unadjusted results. Finally, to study the potential
association of methylation data with clinical and biochemical
parameters, we did a correlational analysis (calculating Spear-
man’s rank correlation coefficients) and we performed multivariate
lineal regression models adjusting for age, BMI, gender, waist
circumference, smoking status, physical inactivity and diabetes
status for each CpG site. Overall R2 values for the models
including CpG methylation values, sex, age, BMI, waist circum-
ference, physical inactivity, smoking status and diabetes status are
given as percentages. This was done to give an estimate of the
association between outcome and methylation. False discovery
rate (FDR) correction was used for multiple comparisons[27]. All
significance tests were 2-tailed and values of P,0.05 were
considered significant. All analyses were conducted using the
statistical software package Stata version 11 and R Bioconductor.
Results
Metabolic profile of the type 2 diabetic patients and
controls
Baseline characteristics of the patients included in the study are
summarized in Table 1. All patients were overweight (mean BMI
of 29.263.7 in type 2 diabetic patients vs. mean BMI of 28.862.5
in controls, P= 0.454). Mean age of all patients was 68 years and
there were no significant differences in gender (66.7% were men in
TCF7L2 Promoter Methylation and Type 2 Diabetes
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the group of cases vs 53.8% in the group of controls, P= 0.072).
Type 2 diabetic patients had a higher waist circumference as
compared to controls (mean waist values of 102.769.5 cm vs.
97.968.0 cm, P= 0.002). Total cholesterol was lower in cases as
compared to controls (total cholesterol mean values of 4.861.0
mmol/L vs. 5.261.1 mmol/L P= 0.002). HOMA-IR was higher
in cases than in controls (2.661.5 vs. 1.860.7 in controls, P,
0.001). HOMA-B was lower in type 2 diabetic patients as
compared to controls (75.7651.1 in type 2 diabetic patients vs
113.66510.6 in controls, P,0.001). Type 2 diabetic patients were
less physically inactive as compared to controls (28% vs. 53.8%,
respectively P,0.001).
Quantitative DNA Methylation analysis in peripheral
blood of TCF7L2 promoter in type 2 diabetic patients and
controls
Methylation levels in DNA from whole blood of 186 subjects
were obtained for 22 sites covering the region between -497 bp
and +186 bp according to the ATG position for the TCF7L2 gene
(ENSG00000148737). The heat map showing the methylation
values (%) for each CpG site analyzed did not reveal a clearly
distinct pattern of methylation between type 2 diabetic patients
and controls in the region analyzed (Figure not shown), however
some significant differences were actually found. Indeed, multi-
variate logistic regression models confirmed that 14 out of the 22
CpGs analyzed (64%) showed significant differences in DNA
methylation values between type 2 diabetic patients and controls
(see adjusted P-values in Table 2). When accounting for multiple
testing in the multivariate logistic regression models, only 13 out of
22 (59%) remained significant (see adjusted Q-values in Table 2).
The unadjusted correlational analysis showed that the methylation
levels of 16 out of 22 CpG sites (73%) were associated with fasting
glucose, 5 out of 22 CpG sites (23%) were associated with HOMA-
IR, 9 out of 22 CpG sites (41%) were associated with HOMA-B, 6
out of 22 CpG sites (27%) with total-cholesterol and 2 out of 22
CpG sites (9%) with LDL-cholesterol (see Table 3). After further
adjustment, only 4 CpG sites remained significantly correlated
with fasting glucose and 1 CpG site with total-cholesterol and
LDL-cholesterol (see Table 3). Explained variance of fasting
glucose was 62% in CpG 9, CpG 17, CpG 25 and CpG 30,
including only adjustment factors. These variances increased to
63%, 66%, 66% and 63%, respectively, after including TCF7L2
methylation in the model, corresponding to an additional
explained variance of 1%, 4%, 4% and 1%, respectively. The
variance explained by CpG 27 methylation alone on total
cholesterol was up to 5% and up to 4% on LDL-cholesterol.
Discussion
In this study, we report the methylation pattern of TCF7L2
promoter from peripheral blood DNA in drug-naı¨ve type 2
diabetic patients and age- and BMI-matched controls. We found
that several CpGs had significant differences between type 2
diabetic patients and controls, although overall the methylation
pattern did not show a clear differential pattern related to T2D.
These results are consistent with previous data of promoter
methylation patterns from peripheral blood DNA where a global
Table 1. Demographic and clinical characteristics of type 2 diabetic patients and age- and BMI-matched controls.
Variable* Type 2 diabetic patients (n =93) Controls (n=93) P Value{
Demographic characteristics
Age, yr 69.169.2 66.6611.7 0.099
BMI, kg/m2 29.263.7 28.862.5 0.454
Waist circumference, cm 102.769.5 97.968.0 0.002
Male sex, (%) 66.7 53.8 0.072
Duration of diabetes, yr 5.464.1
Physical inactivity, % 28.0% 53.8% ,0.001
Never smoked, % 50.5% 61.3% 0.261
Laboratory values
Fasting glucose, (mmol/L) 6.461.2 4.660.3 ,0.001
Glycated hemoglobin, (%) 5.860.6
Fasting insulin, (pmol/L) 55.6628.6 52.4621.0 0.750
HOMA-IR 1 2.661.5 1.860.7 ,0.001
HOMA-B 11 75.7651.1 113.66510.6 ,0.001
Alanine aminotransferase (ALT), (IU/liter) 13.567.9 14.667.3 0.486
Aspartate aminotransferase (AST), (IU/liter) 16.668.2 19.066.0 0.135
Total cholesterol (mmol/L) 4.861.0 5.261.1 0.002
LDL cholesterol (mmol/L) 2.860.8 2.960.8 0.782
HDL cholesterol (mmol/L) 1.360.3 1.460.3 0.262
Triglycerides (mmol/L) 1.460.9 1.360.8 0.338
* Values shown are means 6SD, unless otherwise indicated.
{P values were calculated with the t test for quantitative variables or Chi-square test for categorical ones, except for HOMA-IR, HOMA-B, fasting insulin, where non-
parametric Mann-Whitney U test was applied.
1HOMA-IR was calculated as [Insulin mlU/l x FSG: (mmol/l)/22.5].
11HOMA-B was calculated as (206 FSI)/(FSG 23.5), where FSI is the fasting serum insulin concentration (mU/l) and FSG is fasting serum glucose (mmol/l).
doi:10.1371/journal.pone.0099310.t001
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directional change in methylation levels that would affect all
neighboring CpGs systematically and that would be characteristic
of the disease has not been identified[18,28]. On the other hand, a
recent study found some T2D-related methylation patterns in
peripheral blood DNA[17] but their analysis did not cover the
genomic region we studied. There is great interest to perform
methylation profiling in peripheral blood to find methylation
disease-related associations since specific methylated regions could
be used as potent biomarkers[29]. However, to study how these
differentially methylated regions may play a mechanistic role in
the development of the disease of interest, the methylation analysis
should focus in the tissues relevant for the genes studied. TCF7L2
is highly expressed in beta-cells, followed by colon, brain, small
intestine, monocytes, and lung[30], whereas no expression was
detected in lymphocytes T or B. It has been shown that depletion
of TCF7L2 results in reduced GIP-Receptor levels in pancreatic
islets and in impaired beta-cell function[31]. In our study, we
found that methylation of specific CpG sites on TCF7L2 promoter
in blood was correlated with fasting glucose, total cholesterol and
LDL-cholesterol. In line with our results, it has been recently
shown that beta-cells cultured with high-glucose-lipid medium
presented aberrant DNA methylation in different loci, among
which was TCF7L2 gene promoter[32]. Moreover, Hu et al
showed that, while TCF7L2 promoter was hypermethylated,
TCF7L2 mRNA expression increased, and, unexpectedly, the
protein expression of TCF7L2 was decreased in beta- cells[32].
The mechanisms of this opposite regulation remain unkown,
although it could be speculated that DNA methylation may affect
the TCF7L2 splice variants[33], i.e., the increase in mRNA levels
could represent transcripts of TCF7L2 which would encode less
active isoforms[32]. Methylation patterns are thought to be tissue-
specific[10,34,35], thus we might not extrapolate the methylation
patterns found in blood to those present in beta-cells. As TCF7L2
gene is not expressed in blood lymphocytes, we did not perform
mRNA expression analyses in peripheral blood. Nevertheless, the
first methylome reference in human pancreatic islets has been just
published[36]. Dayeh et al performed a genome-wide DNA
methylation analysis of human pancreatic islets from type 2
diabetic and non-diabetic donors[36]. In this study, TCF7L2 gene
presented differential methylation values in diabetic pancreatic
islets as compared to non-diabetic pancreatic islets. It should be
noted though that the region they studied in TCF7L2 gene is
further downstream (39) than the region we studied.
Type 2 diabetic patients and controls were similar in age and
BMI to control for any confounder effect of age and obesity on the
results. Moreover, none of the type 2 diabetic patients were on any
pharmacological therapy for diabetes. Thus, no confounding effect
of antidiabetic drugs or insulin therapy was possible, either. Type 2
diabetic patients received counselling about exercise and healthy
diet in order to control their diabetes. This could explain why the
% of physically inactive subjects was higher in the control group as
compared to the type 2 diabetic patients. The majority of type 2
diabetic patients (67%) were on statins as compared to controls.
This could explain the differences in mean total cholesterol
between the two groups. Type 2 diabetic patients were in optimal
glycemic control (mean glycated hemoglobin 5.8%) and had their
clinical diagnosis of T2D recently (mean duration of diabetes was
5 years). Results showed that type 2 diabetic patients were more
insulin-resistant than controls, since they presented higher values
of HOMA-IR. In concordance to this, type 2 diabetic patients had
a higher waist circumference as compared to controls. Higher
waist circumference is one component used for the diagnosis of the
metabolic syndrome and previous research showed that it
correlates with poorer glucose control in type 2 diabetic
patients[37]. In contrast, and as expected, beta-cell function was
already impaired in type 2 diabetic patients as compared to
controls (HOMA-B was significantly lower in type 2 diabetic
patients as compared to controls). These data illustrates the fact
that impairment of beta-cell function is worse in type 2 diabetic
patients as compared to age- and BMI- matched controls. These
results are in concordance with the existing literature[38,39,40].
The strength of our research is that we have demonstrated that
type 2 diabetic patients have differences in concrete CpGs sites of
TCF7L2 promoter as compared to age- and BMI-matched
controls. We also found new correlations between fasting glucose,
total cholesterol and LDL-cholesterol with DNA methylation in
specific CpG sites of TCF7L2 promoter in DNA from peripheral
blood. However, despite accounting for the major confounding
factors (age, BMI, diabetes pharmacologic therapy), residual
confounding and reverse causation remain possible[41]. As
proposed by Relton et al[41], by applying a ‘‘genetical epigenomics’’
approach, we could overcome this issue. In our case, the approach
would be to study the genetic variants related to the methylation
patterns and then to verify whether the correlation with
methylation values and fasting glucose and cholesterol remains.
However, this was not the goal of the present study.
In conclusion, the targeted epigenetic analysis in DNA from
peripheral blood identified differences in specific sites of the
TCF7L2 promoter between type 2 diabetic patients and matched
controls. Lipid and glucose blood-parameters were correlated with
methylation in specific CpG sites of the TCF7L2 promoter.
Further research should unveil the potential role of these data in
the physiopathology of T2D. Our findings add to the growing
understanding of the interplay between epigenetics and T2D
susceptibility gene TCF7L2 in the development of the disease.
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